Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer|PD-L1 Positive
Interventions: DRUG: Sacituzumab Govitecan-hziy|DRUG: Pembrolizumab|DRUG: Paclitaxel|DRUG: nab-Paclitaxel|DRUG: Gemcitabine|DRUG: Carboplatin
Sponsor: Gilead Sciences
Collaborators: Merck Sharp & Dohme LLC